Figure 1.
FDA-approved drugs in advanced ovarian cancer
dMMR: deficient mismatch repair, FDA: US Food and Drug Administration, HRD: homologous recombination deficiency, L: line of treatment, MSI: microsatellite instability high, mut: mutated, PlSOC: platinum-sensitive ovarian cancer, PlROC: platinum-resistant ovarian cancer, PLD: pegylated liposomal doxorubicin.